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Summary
Objective: This study investigated non-adherence to antiepileptic drug treatment
amongst patients with epilepsy in secondary care. The associations between adher-
ence and seizure control, perceptions of illness and medication, anxiety and depres-
sion were also examined.
Methods: A cross-sectional study of fifty-four patients with epilepsy were recruited
from a hospital epilepsy clinic.
Results: Fifty-nine percent were estimated to be non-adherent to medication. There
was a negative correlation between adherence and frequency of seizures. Patients
with poorly controlled epilepsy were more anxious, and expected a longer duration of
their epilepsy.
Conclusion: Assessment of adherence should be a routine part of management of
epilepsy. Further recognition and support should be given to patients who have poor
seizure control since they are more likely to be more anxious and have unhelpful
illness and treatment beliefs.
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Epilepsy has a prevalence of between 4 and 10 per
1000 population1,2 and is associated with physical,
psychological and social problems.3 People with epi-
lepsy have a higher rate of suicide, anxiety, depres-
sion, sudden unexplained death and accidentaln behalf of British Epilepsy Association.
Adherence in epilepsy 505death.4,5 Prolonged seizures may cause physical
injury, neuronal death leading to cognitive impair-
ment, and can be fatal.5
When treating an individual with epilepsy, there
are factors that cannot be modified such as the age
of onset, the aetiology of the seizures and the
location of the epileptogenic zone. There are also
some factors that may be amenable to an interven-
tion to improve outcome. An obvious consideration
for the clinician is the choice of medication to
prescribe. Despite medication, it has been found
that seizures persist in 20—35% of cases.6 It is
necessary therefore to identify other ‘‘modifiable
factors’’ which could lead to improved seizure con-
trol if targeted effectively.
Non-adherence to medication is widespread in
chronicdiseaseand is amajorproblemfacingmedical
practice.7 Current estimates of non-adherence in
epilepsy are similar to those in other chronic illnesses
and range from 30 to 50%.8 This reduces the benefit
that could be gained from the medication.7,9 Poor
adherencemaybe themost importantcauseofpoorly
controlled epilepsy.10 Stanaway et al. found that 31%
of seizures were precipitated by non-adherence to
medication.11 If modifable factors associated with
non-adherence are understood, then it may be pos-
sible to intervene to improve adherence and there-
fore reduce morbidity caused by recurrent seizures.
Existing studies suggest that non-adherence is asso-
ciated with frequency of administration of medica-
tion, age and attitude to taking medication.12,13
Beliefs about medication and illness are potentially
modifiable, can be measured using standardised
questionnaires and have been related to adherence
in other populations. In addition to beliefs, emotions
and coping styles may also influence illness beha-
viour.14 A range of theoretical models have been
developed to attempt to clarify the relationships
between beliefs, attitudes and behaviour, including
social learning theory,15 and the self-regulatory
model of Leventhal et al.,16 which was chosen for
the present study.
Adherence is difficult to measure accurately. In
epilepsy adherence has been measured by self-
report, drug-level monitoring and prescription refill
monitoring. Each method has disadvantages. For
example, plasma drug levels are altered by pharma-
cokinetics as well as adherence, require an invasive
procedure and only indicate recent adherence. Med-
ication bottles that electronically record every open-
ing are considered to be the most accurate means of
measuring adherence.9 However, a previous study to
investigate adherence in epilepsy found this method
unreliable.17 Self-reporting is the simplest measure.
Although adherence can be overestimated,17 parti-
cularly due to self-presentation bias,18 specificity isgenerally high (87%).7 George et al.19 have found that
when a valid questionnaire is used (Morisky et al.20),
self-report scores are accurate with both sensitivity
and specificity of over 70%. So far, studies investigat-
ing self-reportedadherence in epilepsy havenotused
validatedquestionnaires.10,12,21—23This studyaims to
investigate theextent towhichnon-adherence,mea-
sured using a validated self-report questionnaire is
associated with poor seizure control. We also aim to
investigate the relationship between seizure control
and beliefs about medication and illness.Methods
Subjects and procedure
We performed a cross-sectional assessment of self-
reported adherence and attitudes to medication. We
obtained approval of the study from the local
research Ethics Committee. We recruited patients
from those registered with a hospital epilepsy clinic.
Patients were included if they had a diagnosis of
epilepsy, were aged between 18 and 60 years, and
were taking at least one antiepileptic drug. Conse-
cutive attenders were asked to participate by the
clinic doctor. The researcher (VT) then contacted
consenting participants who provided questionnaires
to subjects who were asked to complete them and
return by post.
Measures
We obtained the age of onset of epilepsy, recent
seizure frequency and details of prescribed antie-
pileptic drugs from the clinical records. Epilepsy was
arbitrarily defined as ‘‘well controlled’’ if the
patient reported less than one seizure per month.
Questionnaires of known reliability and validity
were used to assess treatment adherence (Morisky
et al. questionnaire20), beliefs about illness (illness
perception questionnaire, IPQ24) and treatment
(beliefs about medicines questionnaire, BMQ25)
and psychological symptoms (hospital anxiety and
depression scale, HAD26). The Morisky scale has four
items with minimum score of 0 and maximum of 4.
Patients were considered non-adherent if they
scored 1 or more. The beliefs about medicines
questionnaire comprises 18 statements, and sub-
jects are asked the extent to which they agree or
disagree with the statement on a five-point scale.
The questionnaire is divided into two sections, mea-
suring beliefs about medicines in general and beliefs
about a specified medication (general and specific
sections). For our study, items in the specific section
were worded to relate to ‘antiepileptic drugs’. The
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(e.g. ‘‘my health at present depends upon my anti-
epileptic drugs’’ and concerns subscales (e.g. ‘‘hav-
ing to takemy antiepileptic drugs worries me’’). The
general section consists of the overuse subscale
(e.g. ‘‘doctors use to many medicines’’), the harm
subscale (e.g. ‘‘medicines do more harm than
good’’). The BMQ items in the four subscales have
a test—retest reliability of between 0.60 and 0.78
and a Cronbach’s alpha of between 0.47 and 0.86.25
The illness perception questionnaire has 38 items
on a four-point scale. The scale is divided into five
subscales: identity (patients attribution of symptoms
such as fatigue and headaches to the illness), time-
line (perception of duration of illness, e.g. ‘‘my ill-
ness will last for a long time’’), consequences
(perceived negative consequences of epilepsy, e.g.
‘‘my illness has hadmajor consequences onmy life’’),
cure—control (belief that epilepsy can be treated,
e.g. ‘‘there is a lot that I can do to control my
symptoms’’) and cause (the perceived cause of the
illness, e.g. ‘‘it was by chance that I developed my
illness’’). The internal consistence as measured by
Cronbach’s alpha ranges from 0.73 to 0.82.24
Analysis
We used the Chi-squared test, Mann—Whitney test,
t-test and Pearson’s correlation as appropriate. We
used non-parametric tests were used due to the
small subgroup samples. Statistical Package for
Social Sciences (SPSS, Version 10; SPSS Inc., 444
North Michigan Avenue, Chicago, IL, USA) was used
for data analysis.Results
Sample
We invited seventy-five people to participate in the
study, of whom 54 (72%) consented. There were noTable 1 Characteristics of patients with well controlled a
Well co
Number 23
Mean age (S.D.) 40.8 (18
Number of males (%) 11 (48%
Mean age at diagnosis of epilepsy in years (S.D.) 26.6 (22
Mean duration of epilepsy in years (S.D.) 18.0 (19
Median number of seizures in last month (IQR) 0 (0—0
Median number of drugs each day (IQR) 2 (1—2
Median daily dosing frequency (IQR) 2 (2—2
Number (%) non-adherent (1 on Morisky) 12 (38%
t = Unpaired Student’s t-test statistic, x2 = chi squared statistic, Zsignificant age or gender differences between par-
ticipants and refusers.
Of the fifty-four participants in the study, 25 (46%)
were male. The mean age of the participants was
38.2 years (standard deviation (S.D.) 16.1 years). The
meanageat diagnosis of epilepsywas 21.8 years (S.D.
19.3) and the mean duration of epilepsy was 18.2
years (S.D. 15.1). The median number of drugs taken
each day by the subjects was 2 (inter-quartile range
(IQR) 1—2) and the median dosing frequency was 2
(IQR 2—2). Using the accepted criterion of a score of
one or more on the Morisky questionnaire indicating
non-adherence, 32 patients (59%) were classified as
non-adherent tomedication. According to our defini-
tion of poor seizure control, 31 patients (57%) had
poor control (Table 1).
There were no significant differences between
well and poorly controlled epilepsy in respect of
patient age, gender, age at diagnosis or duration of
epilepsy. As expected, patients with poorly con-
trolled epilepsy had significantly more seizures than
those with well controlled epilepsy (p < 0.01) and
were prescribed significantly more medications
(p < 0.01), although there was no significant differ-
ence in dosing frequency. There was no significant
overall correlation between adherence and abso-
lute seizure frequency (r = 0.003, p = 0.98). How-
ever, one subject reported over 300 seizures per
month which markedly skewed the distribution.
When this subject was excluded from the analysis
there was a significant positive correlation
(r = 0.344, p = 0.01).
Illness perception and beliefs about
medication
Beliefs about medication scores are shown in
Table 2.
Patients with poorly controlled epilepsy had a
greater belief in the need for medication than well
controlled patients (Table 2). There was a non-sig-
nificant trend for poorly controlled subjects to alsond poorly controlled epilepsy
ntrolled Poorly controlled Test statistic p-Value
31
.3) 36.2 (14.4) t = 1.03 p = 0.31
) 14 (45%) x2 = 0.04 p = 0.85
.4) 18.4 (16.3) t = 1.60 p = 0.13
.5) 17.9 (11.2) t = 0.03 p = 0.98
) 4 (2—12) Z = 6.50 p < 0.01
) 2 (2—3) Z = 1.90 p = 0.05
) 2 (2—3) Z = 0.20 p = 0.10
) 20 (63%) x2 = 1.85 p = 0.17
= Mann—Whitney U statistic.
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Table 2 Comparison of beliefs about medicines questionnaire scores between patients with well and poorly
controlled epilepsy
Well controlled Poorly controlled Statistical test
Overuse median (IQR) 11 (9—14) 12 (8.8—14.3) p = 0.74, Z = 0.33
Harm median (IQR) 9 (8—11) 9 (7.8—10) p = 0.97, Z = 0.04
Necessity median (IQR) 18 (14—20) 21 (18—22) p = 0.02, Z = 2.31
Concern median (IQR) 13 (11—17) 15 (13—19) p = 0.07, Z = 1.82
Table 3 Comparison of illness perception questionnaire scores between patients with well and poorly controlled
Well controlled Poorly controlled Statistical test
Identity median (IQR) 3 (2—6) 5 (4—8) p = 0.09, Z = 1.69
Timeline median (IQR) 10 (8—12) 13 (9—15) p = 0.03, Z = 2.21
Consequences median (IQR) 23 (20—25) 26 (22—28) p = 0.08, Z = 1.76
Cure—control median (IQR) 20 (18—23) 18 (15—21) p = 0.13, Z = 1.52report more concerns with their medication
(Table 2).
Illness perception questionnaire scores are shown
in Table 3. Compared with the well controlled sub-
jects, those with poor control believed that their
epilepsy would last longer. There were no differ-
ences in beliefs about symptom profile of the illness,
perceived cause of illness, perceived negative con-
sequences of epilepsy or belief that epilepsy can be
treated. Poorly controlled patients reported signifi-
cantly more anxiety than well controlled patients
(HAD-A median score 9, IQR 7—12.3 compared to
median 6, IQR 5—8, p = 0.007).Discussion
We found that non-adherence to medication is com-
mon in epilepsy. We found that patents with poorly
controlled epilepsy had beliefs about their epilepsy
that were significantly different from those with
well controlled epilepsy. They had a greater belief
in the need for medication, they expected a greater
duration of their illness and they were also signifi-
cantly more anxious. Our data also suggest that
there is a correlation between seizure frequency
and non-adherence to medication.
The strength of this study was that for the first
time validated questionnaires were used to assess
adherence and beliefs about illness and medication
in epilepsy. Since poor control was associated with
non-adherence, it was surprising that poor control
was not associated with less belief in the need for
medication. The association with concerns was in
the expected direction. Putting these results
together, one may conclude that concerns about
medication outweigh the perceived need in some
patients with epilepsy and this may be associated
with higher levels of anxiety. The associationbetween increased psychological morbidity and
poor control indicates that patients with poor con-
trol are a vulnerable group that may benefit from
increased psychological support.
The finding that seizure control is correlated with
non-adherence indicates that therapy to promote
adherence to medication27 could be an important
part of the treatment strategy provided by a specia-
list clinic. An approach which focuses on the choice
and dose of antiepileptic will have limited success if
the prescribed treatment is not adhered to. It is
possible that general practitioners refer patients
with poor control to secondary care in the belief that
they have failed to find a successful drug treatment,
when it is in factmoreof aproblemwithadherence. It
is not expected that general practitioners will have
the time to conduct regular compliance therapy
sessions, however a brief assessment of adherence
can be made very quickly and with good sensitivity
and specificity using theMorisky questionnaire, and it
has been shown that health behaviour of patients can
be effectively modified in general practice by simple
advice.28 Adherence should be discussed regularly
with the patient, and in particular when a treatment
seems to fail.
There are however a number of potential weak-
nesses of the study. Firstly, the sample size was
relatively small. Although we found a significant
correlation between adherence and seizure fre-
quency, we did not find significant group differences
in adherence between people with well controlled
and poorly controlled epilepsy. It is likely that sig-
nificant results were not detected due to an insuffi-
cient sample size. We would therefore recommend
that future research studies a larger sample. There
is a also potential recruitment bias as only 72% of
those approached agreed to take part. Although the
measures used are all well validated, there is a
potential risk of response bias as they rely on
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corroborate the reports of adherence by other
means which would have added precision to the
measures, though at the expense of patient parti-
cipation and cost. A cross-sectional design cannot
determine causality; poor adherence may occur as a
result of the severity of the illness or non-respon-
siveness to treatment. For example, post-ictal con-
fusion or amnesia may result in inadvertent non-
adherence. Increased dosing frequency and number
of different medications taken in uncontrolled epi-
lepsy would also be expected to affect adherence.
Future research could also include measurements of
more variables than we measured in this study to
explore mechanisms of non-adherence. These may
include coping styles, personality types and motiva-
tion. Other psychological models could also be
investigated.
In secondary care a full assessment of modifiable
factors that could be acted on to improve seizure
control should be made. Non-adherence to medica-
tionmay be the single greatest factor in poor seizure
control and can be quickly and easily assessed.
Adherence assessments should be routine. An
inquiry should be made to examine the unhelpful
beliefs that the patient may have which interfere
with adherence. Given the marked physical, psy-
chological and social dysfunction associated with
poorly controlled epilepsy, and the considerable
financial impact on health services, psychological
input to address adherence may well be a very cost
effective addition to the health care provider’s
armoury. Further studies are needed to evaluate
the effect of adherence on seizure control, to eval-
uate the effect of psychological care in epilepsy, and
to assess its impact on adherence, seizure control
and distress.References
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